TokenPost·
Tezspire Trial Shows Higher EoE Remission Through 52 Weeks
64.8%
histologic remission rate
At 24 weeks, histologic remission reached 64.8% and 68.9% across two doses, versus 3.5% with placebo; swallowing symptom scores also fell.
More news
- TokenPostGoldman Sachs Forecast Points to Lower U.S. Home Sales in 2027
- TokenPostDell Converts Company Practices Into Instructions for AI Agents
- TokenPostBraze Shares Rise 51.7% Tuesday as Most Software Names Advance
- TokenPostOffchain Executive Cites Interest in Tokenized Assets on Arbitrum
- TokenPostExtended Plans Oct. 22 Arc Move as USDT, wBTC Positions Face Closure Risk
- TokenPostSaylor says Strategy will remain a net Bitcoin buyer but may sell to fund dividends